Nu Skin Enterprises (NUS)
(Delayed Data from NYSE)
$6.45 USD
+0.05 (0.78%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $6.44 -0.01 (-0.16%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.45 USD
+0.05 (0.78%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $6.44 -0.01 (-0.16%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth A Momentum A VGM
Zacks News
NUS vs. EL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NUS vs. EL: Which Stock Is the Better Value Option?
Nu Skin (NUS) Q4 Earnings Surpass Estimates, Decrease Y/Y
by Zacks Equity Research
Nu Skin (NUS) delivers better-than-expected fourth-quarter 2018 results, wherein the top line improves year over year on solid performances across most regional segments.
Nu Skin Enterprises (NUS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 1.94% and 1.48%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Currency be a Drag on Nu Skin's (NUS) Q4 Earnings?
by Zacks Equity Research
Nu Skin's (NUS) Q4 results to be hurt by weak gross margin and unfavorable currency translations. Nevertheless, expanding customer base and sales leaders are likely to offer respite.
Earnings Preview: Nu Skin Enterprises (NUS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Nu Skin's Sales Leaders & Customers Revive Lost Sheen?
by Zacks Equity Research
Nu Skin (NUS) grapples with sluggish gross margin and adverse currency trends. Nevertheless, strength in sales leaders and customers are encouraging.
Can Growth in Sales Leaders Uplift Nu Skin Stock in 2019?
by Zacks Equity Research
Nu Skin (NUS) is reeling under soft margins and adverse impacts from currency fluctuations. However, sturdy base of sales leaders and customers is likely to enhance performance.
Why Is Nu Skin (NUS) Up 1.5% Since Last Earnings Report?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Nu Skin Enterprises (NUS)
by Zacks Equity Research
Nu Skin Enterprises (NUS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Nu Skin (NUS) Stock Down on Q3 Earnings Miss, Sales Rise Y/Y
by Zacks Equity Research
Negative currency translation weighs on Nu Skin's (NUS) Q3 performance. Nevertheless, sales leaders and customer count continues to rise.
Nu Skin Enterprises (NUS) Misses Q3 Earnings Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of -2.08% and 1.75%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Sales Leaders & Customers to Aid Nu Skin's (NUS) Q3 Earnings
by Zacks Equity Research
Nu Skin's (NUS) Q3 performance to gain from a sturdy base of sales leaders and customers. Projections for the impending quarter unveil a favorable picture.
Factors Likely to Influence Meredith's (MDP) Q1 Earnings
by Zacks Equity Research
While strategic buyouts and restructuring actions serve as key growth drivers for Meredith (MDP), soft EBITDA margins may be a deterrent.
Will Monster Beverage (MNST) Beat Earnings Estimates in Q3?
by Zacks Equity Research
Monster Beverage (MNST) benefits from product innovation strategy and regular product launches. Latest additions to the Monster brand are likely to generate incremental sales and boost profitability.
Can Keurig Dr Pepper (KDP) Deliver Earnings Beat in Q3?
by Zacks Equity Research
Keurig Dr Pepper (KDP) is poised to gain from DPS' distribution strategy and innovation alongside Keurig's coffee brands and online presence. But, soft CSD trends and higher aluminum prices are woes.
Is Archer Daniels (ADM) Poised for Earnings Beat in Q3?
by Zacks Equity Research
Archer Daniels (ADM) saw a stellar start to 2018, having beaten earnings and sales in the first two quarters of 2018. Do strategies position it for a Q3 beat?
Medifast (MED) Q3 Earnings: Coaches & OPTAVIA are Key Drivers
by Zacks Equity Research
Medifast's (MED) Q3 performance to gain from a sturdy coach base and advancement in the OPTAVIA brand.
Nu Skin Enterprises (NUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Nu Skin (NUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avon Products (AVP) is on Track for Turnaround: Here's Why
by Zacks Equity Research
Avon (AVP) focuses on boosting growth of Representatives, which is a key factor for the success of its direct-selling business. However, investors are wary of its dismal top and bottom-line trends.
Rising Sales Leaders & Customers Adorn Nu Skin's Performance
by Zacks Equity Research
Nu Skin's (NUS) top line benefits from growth in sales leaders and customers. Further, the company focuses on empowering sales leaders through effective compensations.
Avon Announces Long-Term Financial Targets & Growth Strategy
by Zacks Equity Research
Avon Products (AVP) announces long-term financial targets, backed by its new "Open Up Avon" strategy.
Avon to Consolidate US Operations Into New York Facility
by Zacks Equity Research
Avon (AVP) is making efforts to simplify its U.S. business in a bid to fuel growth. However, this move will lead to head count reductions of roughly 100 employees.
Avon Stock Rallies on Takeover Talks With Brazil's Natura
by Zacks Equity Research
Avon (AVP) gains on rumors of a possible buyout by Natura & Co, the leading Brazilian cosmetics company.
Nu Skin Enterprises Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Nu Skin Enterprises has been struggling lately, but the selling pressure may be coming to an end soon.
5 Reasons Why Helen of Troy Stock Must be in Your Portfolio
by Zacks Equity Research
Helen of Troy (HELE) is likely to keep its stellar show on, evident from its raised earnings outlook for fiscal 2019.